ArticleMagma (New York, N.Y.)2026
Influence of gadolinium-based contrast agent (GBCA) on the diffusion weightings of breast lesions: an intra-patient analysis.
Article in Magma (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the influence of gadolinium-based contrast agent (GBCA) administration on breast lesions' signal intensities on diffusion-weighted images and its derived ADC maps acquired 2 min after GBCA administration. MATERIALS AND
methodsAn intra-patient analysis was performed. 110 lesions > 5 mm in 93 patients, visible on screening and pre-operative MRI scans at 1.5 T and 3.0 T, were included. Pre-contrast and post-contrast DWI were acquired with single-shot spin-echo echo-planar imaging (SSh-SE-EPI) with b0, b50, b150, and b800 diffusion weightings. 2D regions of interest were drawn. Each b value was separately analyzed regarding signal intensities on DWI. Furthermore, ADC values were compared based on the pairs b0-b800 and b150-b800. The comparison between pre- and post-contrast DWIs was investigated within and between different groups (overall, malignant/benign, and at 1.5/3.0 T). The Wilcoxon-signed rank test and independent Student T test were used when appropriate. P < 0.01 was considered as statistically significant.
resultsOverall, and for malignant and benign lesions separately, a significant change after contrast administration in signal intensity was observed at each specific b value, irrespective of the use of 1.5 T or 3.0 T. The effect of contrast administration was overall notably different when comparing b0 (+ 9.4%) vs. b800 (+ 11.8%), but this was not observed between b150 (11.4%) and b800 (11.8%) (P = 0.10). In malignant lesions, specifically, all b value pairs, except b0-b50, showed significant differences in GBCA effects. This translates into a pre-post-contrast difference of the ADC value of 3.2% (P = 0.02) when based on b0-b800 and 0.9% (P = 0.11) when using b150-800.
conclusionsThere is a limited, but significant effect of contrast administration on DW signal intensities measured 2 min after contrast administration. This effect is not the same for each b value. Signal change is stronger for high than for low b values, which leads to a larger change in measured ADC values after contrast administration when b0 and b50 are incorporated in the calculation. As a consequence, ADC calculations obtained from b150-b800 seem to be more robust than those obtained from b0-b800.
Indexed as
Identifiers
42371335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.